Overview

Cagrilintide is a novel long-acting amylin analog developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. As a synthetic analog of the naturally occurring hormone amylin, cagrilintide mimics the physiological effects of amylin while providing extended duration of action through structural modifications that extend its half-life to approximately 7 days.

Research indicates that cagrilintide works synergistically with GLP-1 receptor agonists, particularly semaglutide, in the combination product known as CagriSema. Clinical studies suggest this combination may provide superior weight loss and glycemic control compared to either agent alone. The peptide is currently undergoing Phase 3 clinical trials for weight management in adults with overweight or obesity, both with and without type 2 diabetes.

Cagrilintide represents a significant advancement in peptide-based obesity therapeutics, offering once-weekly dosing convenience and potentially enhanced efficacy when combined with established GLP-1 therapies.

Mechanism of Action

Cagrilintide functions as an amylin receptor agonist, binding to and activating amylin receptors located primarily in the area postrema of the brainstem. These receptors are part of the body's natural satiety signaling system and play a crucial role in regulating food intake and gastric emptying.

Upon activation, cagrilintide triggers several physiological responses that contribute to weight loss and improved glycemic control:

Satiety Enhancement: Studies indicate that cagrilintide increases feelings of fullness and reduces food intake by modulating neural pathways in the hypothalamus that control appetite and meal termination.

Gastric Emptying Regulation: Research suggests the peptide slows gastric emptying, leading to prolonged nutrient absorption and enhanced satiety signals. This mechanism helps reduce overall caloric intake by extending the feeling of fullness after meals.

Glucagon Suppression: Clinical data shows cagrilintide may suppress inappropriate glucagon release from pancreatic alpha cells, particularly in the postprandial state, contributing to improved glucose homeostasis.

Synergistic Effects with GLP-1: When combined with GLP-1 receptor agonists like semaglutide, cagrilintide appears to provide complementary mechanisms of action, with amylin pathways enhancing the effects of incretin-based therapies.

The extended half-life of cagrilintide, achieved through structural modifications that resist peptidase degradation, allows for once-weekly administration while maintaining consistent receptor activation throughout the dosing interval.

Research Summary

Clinical development of cagrilintide has progressed rapidly, with 10 published studies and 5 registered clinical trials demonstrating its potential as a weight management therapy.

Key Studies

Phase 2 Dose-Finding Trial (2021, Lancet): A multicentre, randomised, double-blind, placebo-controlled trial evaluated once-weekly cagrilintide doses from 0.6 mg to 4.8 mg in adults with overweight or obesity. The study demonstrated dose-dependent weight loss, with the highest doses achieving mean weight reductions of 10.8% over 26 weeks. Gastrointestinal side effects were the most common adverse events, occurring in a dose-dependent manner.

CagriSema Combination Study (2023, Lancet): A Phase 2 trial examined co-administered cagrilintide 2.4 mg with semaglutide 2.4 mg in participants with type 2 diabetes. Results indicated superior glycemic control and weight loss compared to semaglutide monotherapy, with HbA1c reductions of 2.2% and weight loss of 15.6% over 32 weeks.

Phase 3 Obesity Trial (2025, NEJM): The REDEFINE-1 study evaluated CagriSema versus semaglutide 2.4 mg in 3,400 adults with obesity. Participants receiving the combination achieved mean weight loss of 22.7% versus 16.1% with semaglutide alone. The combination was generally well-tolerated, with similar rates of gastrointestinal adverse events.

Type 2 Diabetes Phase 3 (2025, NEJM): The REDEFINE-2 trial studied CagriSema in 1,900 adults with overweight/obesity and type 2 diabetes. The combination demonstrated superior efficacy for both weight loss (16.1% vs 8.1%) and glycemic control (HbA1c reduction 2.4% vs 1.8%) compared to semaglutide monotherapy.

Safety and Pharmacokinetics (2021, Lancet): A Phase 1b trial established the safety profile of concomitant cagrilintide and semaglutide administration. The study confirmed no significant pharmacokinetic interactions and established the dosing regimen used in subsequent Phase 3 trials.

Clinical Trial Pipeline

Five active clinical trials are evaluating cagrilintide across multiple indications:

• NCT05567796: Phase 3 trial comparing CagriSema to semaglutide for weight management (ACTIVE)
• NCT06388187: Phase 3 dose optimization study for CagriSema (ACTIVE)
• NCT07282613: Phase 3 glycemic control study in type 2 diabetes (RECRUITING)
• NCT06131372: Phase 2 kidney protection study (COMPLETED)
• NCT07357740: Phase 2 device comparison study (PLANNED)

Dosage Guidelines

Based on clinical trial data, cagrilintide dosing follows an escalation protocol to minimize gastrointestinal side effects while achieving therapeutic efficacy.

Dose Escalation Schedule (based on Phase 2/3 protocols):

• Weeks 1-4: 0.6 mg weekly
• Weeks 5-8: 1.2 mg weekly
• Weeks 9-12: 1.8 mg weekly
• Week 13+: 2.4 mg weekly (maintenance)

Administration Guidelines:

• Inject subcutaneously in abdomen, thigh, or upper arm
• Rotate injection sites to prevent lipodystrophy
• Can be administered with or without food
• If dose missed, take within 3 days; otherwise skip and resume regular schedule

Combination Protocols: When used with semaglutide (CagriSema), both peptides follow parallel escalation schedules, with each component reaching 2.4 mg weekly by week 13.

Safety Profile

Clinical trials indicate cagrilintide has a generally manageable safety profile, with most adverse events being gastrointestinal and transient.

Common Side Effects (>10% incidence):

• Nausea: 45-60% of participants, typically mild-moderate and decreasing over time
• Vomiting: 25-35%, more common during dose escalation
• Diarrhea: 20-30%, usually resolving within 4-8 weeks
• Constipation: 15-25%, may be persistent in some individuals
• Abdominal pain: 15-20%, generally mild

Less Common Side Effects (1-10%):

• Injection site reactions (erythema, swelling)
• Headache
• Fatigue
• Dizziness
• Hypoglycemia (when combined with insulin or sulfonylureas)

Serious Adverse Events (<1%):

• Pancreatitis: Rare cases reported, similar to other incretin-based therapies
• Gastroparesis: Risk increased in susceptible individuals
• Severe hypoglycemia: When combined with insulin or insulin secretagogues

Monitoring Recommendations:

• Regular assessment of gastrointestinal symptoms
• Blood glucose monitoring in diabetic patients
• Periodic evaluation of pancreatic enzymes if abdominal pain occurs
• Weight and BMI tracking
• Assessment of eating behaviors and appetite changes

Discontinuation Criteria:

• Persistent severe nausea/vomiting despite dose reduction
• Signs or symptoms of pancreatitis
• Severe gastroparesis
• Inadequate weight loss response after 16-20 weeks at maximum tolerated dose

Stacking

Cagrilintide is primarily studied and used in combination with GLP-1 receptor agonists, particularly semaglutide, in the proprietary combination known as CagriSema.

Primary Combination:

Cagrilintide + Semaglutide (CagriSema)

• Rationale: Complementary mechanisms targeting both amylin and GLP-1 pathways
• Dosing: Both peptides escalated to 2.4 mg weekly
• Synergy: Research suggests 40-50% greater weight loss than semaglutide alone
• Timing: Can be administered as separate injections or combination formulation

Theoretical Combinations (not clinically studied):

Cagrilintide + Tirzepatide

• Consideration: Dual incretin agonist plus amylin analog
• Risk: Potentially excessive GI effects and hypoglycemia
• Status: No published safety or efficacy data

Cagrilintide + Insulin

• Indication: Type 1 diabetes or advanced type 2 diabetes
• Caution: Increased hypoglycemia risk requires careful monitoring
• Adjustment: Insulin doses may need reduction of 25-50%

Contraindicated Combinations:

• Multiple amylin analogs: No evidence supporting benefit, increased adverse events
• Rapid-acting insulin with meals: Competing effects on gastric emptying
• Gastric motility inhibitors: Additive gastroparesis risk

Supportive Therapies:

• Metformin: Compatible, may enhance metabolic benefits
• SGLT-2 inhibitors: Complementary mechanisms, requires monitoring for dehydration
• Lifestyle interventions: Enhanced efficacy with dietary counseling and exercise programs

The optimal approach appears to be the clinically validated CagriSema combination, with other pairings requiring careful medical supervision and monitoring protocols not yet established in clinical trials.

References

1. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. (2025). The New England journal of medicine. DOI PubMed
2. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. (2024). BMJ (Clinical research ed.). DOI PubMed
3. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. (2025). The New England journal of medicine. DOI PubMed
4. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. (2021). Lancet (London, England). DOI PubMed
5. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. (2023). Lancet (London, England). DOI PubMed
6. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. (2024). Cardiology in review. DOI PubMed
7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. (2021). Lancet (London, England). DOI PubMed
8. Development of Cagrilintide, a Long-Acting Amylin Analogue. (2021). Journal of medicinal chemistry. DOI PubMed
9. An update on peptide-based therapies for type 2 diabetes and obesity. (2023). Peptides. DOI PubMed
10. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (2025). Expert opinion on investigational drugs. DOI PubMed